Navigation Links
Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux

ROCHESTER, N.Y., Oct. 5 /PRNewswire/ -- Bausch & Lomb, the global eye health company, today announced it has acquired the commercial assets of Tubilux Pharma S.p.A.

Tubilux is a privately held ophthalmic pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products primarily in Italy, and with distribution in approximately 30 other countries.

Under the terms of the agreement, Bausch & Lomb has acquired the company's ophthalmic pharmaceuticals portfolio, as well as its commercial and sales operations. Group Tubilux will retain its manufacturing operation, producing existing products for Bausch & Lomb under a multi-year contract.

"This agreement more than doubles our presence in the Italian ophthalmic pharmaceuticals market," said Charl van Zyl, head of Bausch & Lomb's Pharmaceuticals business for Europe, Middle East and Africa. "Bausch & Lomb is committed to expanding our portfolio offerings, and we believe that this investment will prove successful for the company, doctors and patients alike."

The acquired Tubilux portfolio includes products for dry eye relief (Oxyal, Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); for anti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).

"As a result of this transaction, Tubilux will strengthen its focus and presence in the ophthalmic pharmaceutical contract manufacturing sector, including ointments, gels and eye drop formats," said Emidio Fedeli, chief executive officer of Group Tubilux.

Sal Oppenheim Jr. & Cie. KGaA Milan Branch acted as the sole financial advisor of Group Tubilux in this transaction.

Financial terms of the agreement will not be made public.

About Bausch & Lomb

Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at

SOURCE Bausch & Lomb

SOURCE Bausch & Lomb
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
2. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
3. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
4. Robbins & Myers Announces Regular Quarterly Cash Dividend
5. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
6. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
9. U.S. Preventive Medicine Acquires Specialty Disease Management
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
Post Your Comments:
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... Dec. 1, 2015 Express Scripts (NASDAQ: ESRX ... IMMY ) to drive access to a low-cost alternative ... of toxoplasmosis that has been recently priced out of reach ... immune systems. --> --> ... leucovorin (a form of folic acid) for $1 per capsule for ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):